Skip to main content
Top
Published in: Indian Journal of Pediatrics 3/2024

13-06-2023 | Ascites | Review Article

Ascites and Chronic Liver Disease in Children

Authors: Rishi Bolia, Anshu Srivastava

Published in: Indian Journal of Pediatrics | Issue 3/2024

Login to get access

Abstract

Development of ascites in children with chronic liver disease is the most common form of decompensation. It is associated with a poor prognosis and increased risk of mortality. A diagnostic paracentesis should be performed in liver disease patients with- new-onset ascites, at the beginning of each hospital admission and when ascitic fluid infection (AFI) is suspected. The routine analysis includes cell count with differential, bacterial culture, ascitic fluid total protein and albumin. A serum albumin-ascitic fluid albumin gradient of ≥1.1 g/dL confirms the diagnosis of portal hypertension. Ascites has been reported in children with non-cirrhotic liver disease like acute viral hepatitis, acute liver failure and extrahepatic portal venous obstruction. The main steps in management of cirrhotic ascites include dietary sodium restriction, diuretics and large-volume paracentesis. Sodium should be restricted to maximum of 2 mEq/kg/d (max 90 mEq/d) of sodium/day. Oral diuretic therapy comprises of aldosterone antagonists (e.g., spironolactone) with or without loop-diuretics (e.g., furosemide). Once the ascites is mobilized, the diuretics should be gradually tapered to the minimum effective dosage. Tense ascites should be managed with a large-volume paracentesis (LVP) preferably with albumin infusion. Therapeutic options for refractory ascites include recurrent LVP, transjugular intrahepatic porto-systemic shunt and liver transplantation. AFI (fluid neutrophil count ≥250/mm3) is an important complication, and requires prompt antibiotic therapy. Hyponatremia, acute kidney injury, hepatic hydrothorax and hernias are the other complications.
Literature
1.
go back to reference Kassam AF, Goddard GR, Johnston ME, et al. Natural course of pediatric portal hypertension. Hepatol Commun. 2020;4:1346–52.CrossRef Kassam AF, Goddard GR, Johnston ME, et al. Natural course of pediatric portal hypertension. Hepatol Commun. 2020;4:1346–52.CrossRef
2.
go back to reference Mahajan S, Lal BB, Sood V, Khillan V, Khanna R, Alam S. Difficult-to-treat ascitic fluid infection is a predictor of transplant-free survival in childhood decompensated chronic liver disease. Indian J Gastroenterol. 2020;39:465–72.CrossRefPubMed Mahajan S, Lal BB, Sood V, Khillan V, Khanna R, Alam S. Difficult-to-treat ascitic fluid infection is a predictor of transplant-free survival in childhood decompensated chronic liver disease. Indian J Gastroenterol. 2020;39:465–72.CrossRefPubMed
3.
go back to reference Nightingale S, Stormon MO, O’Loughlin EV, et al. Early post hepatoportoenterostomy predictors of native liver survival in biliary atresia. J Pediatr Gastroenterol Nutr. 2017;64:203–9.CrossRefPubMed Nightingale S, Stormon MO, O’Loughlin EV, et al. Early post hepatoportoenterostomy predictors of native liver survival in biliary atresia. J Pediatr Gastroenterol Nutr. 2017;64:203–9.CrossRefPubMed
4.
go back to reference Shneider BL, Magee JC, Karpen SJ, et al; Childhood Liver Disease Research Network (ChiLDReN). Total serum bilirubin within 3 mo of hepatoportoenterostomy predicts short- term outcomes in biliary atresia. J Pediatr. 2016;170:211–7.e1–2. Shneider BL, Magee JC, Karpen SJ, et al; Childhood Liver Disease Research Network (ChiLDReN). Total serum bilirubin within 3 mo of hepatoportoenterostomy predicts short- term outcomes in biliary atresia. J Pediatr. 2016;170:211–7.e1–2.
5.
go back to reference Kathuria R, Srivastava A, Yachha SK, Poddar U, Baijal SS. Budd-Chiari syndrome in children: Clinical features, percutaneous radiological intervention, and outcome. Eur J Gastroenterol Hepatol. 2014;26:1030–8.CrossRefPubMed Kathuria R, Srivastava A, Yachha SK, Poddar U, Baijal SS. Budd-Chiari syndrome in children: Clinical features, percutaneous radiological intervention, and outcome. Eur J Gastroenterol Hepatol. 2014;26:1030–8.CrossRefPubMed
6.
go back to reference Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. J Pediatr Gastroenterol Nutr. 2011;52:503–13.CrossRefPubMed Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. J Pediatr Gastroenterol Nutr. 2011;52:503–13.CrossRefPubMed
7.
go back to reference Chongtham DS, Singh MM, Kalantri SP, Pathak S, Jain AP. Accuracy of clinical manoeuvres in detection of minimal ascites. Indian J Med Sci. 1998;52:514–20.PubMed Chongtham DS, Singh MM, Kalantri SP, Pathak S, Jain AP. Accuracy of clinical manoeuvres in detection of minimal ascites. Indian J Med Sci. 1998;52:514–20.PubMed
8.
go back to reference Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014–48.CrossRefPubMed Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1014–48.CrossRefPubMed
9.
go back to reference Chokchaijaroensri D, Arrunyagasamesuke A, Pongprasobchai S. Efficacy of disposable needles versus angiocath needles for therapeutic abdominal paracentesis. J Med Assoc Thai. 2011;94:S154–8.PubMed Chokchaijaroensri D, Arrunyagasamesuke A, Pongprasobchai S. Efficacy of disposable needles versus angiocath needles for therapeutic abdominal paracentesis. J Med Assoc Thai. 2011;94:S154–8.PubMed
10.
go back to reference Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–107.CrossRef Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–107.CrossRef
11.
go back to reference Karnsakul W, Wasuwanich P, Ingviya T, et al. Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites. Clin Res Hepatol Gastroenterol. 2021;45:101549.CrossRefPubMed Karnsakul W, Wasuwanich P, Ingviya T, et al. Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites. Clin Res Hepatol Gastroenterol. 2021;45:101549.CrossRefPubMed
12.
go back to reference Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum ascites albumin gradient in the differential diagnosis of ascites is superior to the exudate/ transudate concept. Ann Intern Med. 1992;117:215–20.CrossRefPubMed Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum ascites albumin gradient in the differential diagnosis of ascites is superior to the exudate/ transudate concept. Ann Intern Med. 1992;117:215–20.CrossRefPubMed
13.
go back to reference Hoefs JC. Globulin correction of the albumin gradient: Correlation with measured serum to ascites colloid osmotic pressure gradients. Hepatology. 1992;16:396–403.CrossRefPubMed Hoefs JC. Globulin correction of the albumin gradient: Correlation with measured serum to ascites colloid osmotic pressure gradients. Hepatology. 1992;16:396–403.CrossRefPubMed
14.
go back to reference Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club J Hepatol. 2000;32:142–53.PubMed Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club J Hepatol. 2000;32:142–53.PubMed
15.
go back to reference Moore P, Wong F, Ginés P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–66.CrossRefPubMed Moore P, Wong F, Ginés P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38:258–66.CrossRefPubMed
16.
go back to reference Ginés P, Angeli P, Lenz K, et al; European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417. Ginés P, Angeli P, Lenz K, et al; European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.
17.
18.
go back to reference Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial. J Hepatol. 1999;30:639–45.CrossRefPubMed Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial. J Hepatol. 1999;30:639–45.CrossRefPubMed
19.
go back to reference Kramer RE, Sokol RJ, Yerushalmi B, et al. Large- volume paracentesis in the man-agement of ascites in children. J Pediatr Gastroenterol Nutr. 2001;33:245–9.PubMed Kramer RE, Sokol RJ, Yerushalmi B, et al. Large- volume paracentesis in the man-agement of ascites in children. J Pediatr Gastroenterol Nutr. 2001;33:245–9.PubMed
20.
go back to reference Sen Sarma M, Yachha SK, Bhatia V, Srivastava A, Poddar U. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol. 2015;63:1126–32.CrossRefPubMed Sen Sarma M, Yachha SK, Bhatia V, Srivastava A, Poddar U. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol. 2015;63:1126–32.CrossRefPubMed
21.
go back to reference Singh SK, Sen Sarma M, Yadav R, et al. Prognostic scoring systems and outcome of endovascular radiological intervention of chronic Budd-Chiari syndrome in children. Liver Int. 2018;38:1308–15.CrossRefPubMed Singh SK, Sen Sarma M, Yadav R, et al. Prognostic scoring systems and outcome of endovascular radiological intervention of chronic Budd-Chiari syndrome in children. Liver Int. 2018;38:1308–15.CrossRefPubMed
22.
go back to reference Mahadeo KM, Bajwa R, Abdel-Azim H, et al; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network and the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: An international expert position statement. Lancet Haematol. 2020;7:e61–72. Mahadeo KM, Bajwa R, Abdel-Azim H, et al; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network and the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: An international expert position statement. Lancet Haematol. 2020;7:e61–72.
23.
go back to reference Chindaratana K, Tanpowpong P, Lertudomphonwanit C, Treepongkaruna S. Gastrointestinal protein loss in children with portal hypertension. Indian J Gastroenterol. 2021;40:333–7.CrossRefPubMed Chindaratana K, Tanpowpong P, Lertudomphonwanit C, Treepongkaruna S. Gastrointestinal protein loss in children with portal hypertension. Indian J Gastroenterol. 2021;40:333–7.CrossRefPubMed
24.
go back to reference Di Giorgio A, Agazzi R, Alberti D, Colledan M, D’Antiga L. Feasibility and efficacy of transjugular intrahepatic porto-systemic shunt (TIPS) in children. J Pediatr Gastroenterol Nutr. 2012;54:594–600.CrossRefPubMed Di Giorgio A, Agazzi R, Alberti D, Colledan M, D’Antiga L. Feasibility and efficacy of transjugular intrahepatic porto-systemic shunt (TIPS) in children. J Pediatr Gastroenterol Nutr. 2012;54:594–600.CrossRefPubMed
25.
go back to reference Bertino F, Hawkins CM, Shivaram G, et al. Technical feasibility and clinical effectiveness of transjugular intrahepatic portosystemic shunt creation in pediatric and adolescent patients. J Vasc Interv Radiol. 2019;30:178–86.e5.CrossRefPubMed Bertino F, Hawkins CM, Shivaram G, et al. Technical feasibility and clinical effectiveness of transjugular intrahepatic portosystemic shunt creation in pediatric and adolescent patients. J Vasc Interv Radiol. 2019;30:178–86.e5.CrossRefPubMed
26.
go back to reference Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133:825–34.CrossRefPubMed Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133:825–34.CrossRefPubMed
27.
go back to reference Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther. 2012;36:619–26.CrossRefPubMed Dahl E, Gluud LL, Kimer N, Krag A. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther. 2012;36:619–26.CrossRefPubMed
29.
go back to reference Caraceni P, Riggio O, Angeli P, et al. Long- term albumin administration in decompensated cirrhosis (ANSWER): An open- label randomised trial. Lancet. 2018;391:2417–29.CrossRefPubMed Caraceni P, Riggio O, Angeli P, et al. Long- term albumin administration in decompensated cirrhosis (ANSWER): An open- label randomised trial. Lancet. 2018;391:2417–29.CrossRefPubMed
30.
go back to reference Sola E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver trans-plantation. A randomized placebo-controlled trial J Hepatol. 2018;69:1250–9.PubMed Sola E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver trans-plantation. A randomized placebo-controlled trial J Hepatol. 2018;69:1250–9.PubMed
31.
go back to reference Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69:1127–38.CrossRefPubMed Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69:1127–38.CrossRefPubMed
32.
go back to reference Defert C, Marret JB, Lacaille F, et al. Peritoneovenous shunt for intractable ascites in children: A series of 4 cases. J Pediatr Gastroenterol Nutr. 2021;73:e7–10.CrossRefPubMed Defert C, Marret JB, Lacaille F, et al. Peritoneovenous shunt for intractable ascites in children: A series of 4 cases. J Pediatr Gastroenterol Nutr. 2021;73:e7–10.CrossRefPubMed
33.
go back to reference Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int. 2019;39:1080–8.CrossRefPubMed Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int. 2019;39:1080–8.CrossRefPubMed
34.
go back to reference Macken L, Corrigan M, Prentice W, et al. British Association for the Study of the Liver/British Society of Gastroenterology (BASL/BSG) End of Life Special Interest Group. Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: A consensus document. Frontline Gastroenterol. 2022;13:e116–25. Macken L, Corrigan M, Prentice W, et al. British Association for the Study of the Liver/British Society of Gastroenterology (BASL/BSG) End of Life Special Interest Group. Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: A consensus document. Frontline Gastroenterol. 2022;13:e116–25.
35.
go back to reference Srivastava A, Malik R, Bolia R, Yachha SK, Poddar U. Prevalence, clinical profile, and outcome of ascitic fluid infection in children with liver disease. J Pediatr Gastroenterol Nutr. 2017;64:194–9.CrossRefPubMed Srivastava A, Malik R, Bolia R, Yachha SK, Poddar U. Prevalence, clinical profile, and outcome of ascitic fluid infection in children with liver disease. J Pediatr Gastroenterol Nutr. 2017;64:194–9.CrossRefPubMed
36.
go back to reference Vieira SMG, Matte U, Kieling CO, et al. Infected and noninfected ascites in pediatric patients. J Pediatr Gastroenterol Nutr. 2005;40:289–94.CrossRefPubMed Vieira SMG, Matte U, Kieling CO, et al. Infected and noninfected ascites in pediatric patients. J Pediatr Gastroenterol Nutr. 2005;40:289–94.CrossRefPubMed
37.
go back to reference Preto-Zamperlini M, Farhat SCL, Perondi MBM, et al. Elevated C-reactive protein and spontaneous bacterial peritonitis in children with chronic liver disease and ascites. J Pediatr Gastroenterol Nutr. 2014;58:96–8.CrossRefPubMed Preto-Zamperlini M, Farhat SCL, Perondi MBM, et al. Elevated C-reactive protein and spontaneous bacterial peritonitis in children with chronic liver disease and ascites. J Pediatr Gastroenterol Nutr. 2014;58:96–8.CrossRefPubMed
38.
go back to reference Singh SK, Poddar U, Mishra R, Srivastava A, Yachha SK. Ascitic fluid infection in children with liver disease: Time to change empirical antibiotic policy. Hepatol Int. 2020;14:138–44.CrossRefPubMed Singh SK, Poddar U, Mishra R, Srivastava A, Yachha SK. Ascitic fluid infection in children with liver disease: Time to change empirical antibiotic policy. Hepatol Int. 2020;14:138–44.CrossRefPubMed
39.
go back to reference Vieira SMG, Schwengber FP, Melere M, Ceza MR, Souza M, Kieling CO. The first episode of spontaneous bacterial peritonitis is a threat event in children with end-stage liver disease. Eur J Gastroenterol Hepatol. 2018;30:323–7.CrossRefPubMed Vieira SMG, Schwengber FP, Melere M, Ceza MR, Souza M, Kieling CO. The first episode of spontaneous bacterial peritonitis is a threat event in children with end-stage liver disease. Eur J Gastroenterol Hepatol. 2018;30:323–7.CrossRefPubMed
40.
go back to reference Bajaj JS, Tandon P, O’Leary JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis. Am J Gastroenterol. 2018;113:1339–44.CrossRefPubMed Bajaj JS, Tandon P, O’Leary JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis. Am J Gastroenterol. 2018;113:1339–44.CrossRefPubMed
41.
go back to reference Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P. Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion: A report of three cases. J Clin Res Pediatr Endocrinol. 2017;9:288–92.CrossRefPubMedPubMedCentral Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P. Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion: A report of three cases. J Clin Res Pediatr Endocrinol. 2017;9:288–92.CrossRefPubMedPubMedCentral
42.
go back to reference Hsu E, Schladt DP, Wey A, Perito ER, Israni AK. Improving the predictive ability of the pediatric end-stage liver disease score for young children awaiting liver transplant. Am J Transplant. 2021;21:222–8.CrossRefPubMed Hsu E, Schladt DP, Wey A, Perito ER, Israni AK. Improving the predictive ability of the pediatric end-stage liver disease score for young children awaiting liver transplant. Am J Transplant. 2021;21:222–8.CrossRefPubMed
43.
go back to reference Yachha SK, Goel A, Khanna V, Poddar U, Srivastava A, Singh U. Ascitic form of sporadic acute viral hepatitis in children: A distinct entity for recognition. J Pediatr Gastroenterol Nutr. 2010;50:184–7.CrossRef Yachha SK, Goel A, Khanna V, Poddar U, Srivastava A, Singh U. Ascitic form of sporadic acute viral hepatitis in children: A distinct entity for recognition. J Pediatr Gastroenterol Nutr. 2010;50:184–7.CrossRef
44.
go back to reference Sen Sarma M, Srivastava A, Yachha SK, Poddar U. Ascites in children with extrahepatic portal venous obstruction: Etiology, risk factors and outcome. Dig Liver Dis. 2020;52:1480–5.CrossRefPubMed Sen Sarma M, Srivastava A, Yachha SK, Poddar U. Ascites in children with extrahepatic portal venous obstruction: Etiology, risk factors and outcome. Dig Liver Dis. 2020;52:1480–5.CrossRefPubMed
45.
Metadata
Title
Ascites and Chronic Liver Disease in Children
Authors
Rishi Bolia
Anshu Srivastava
Publication date
13-06-2023

Other articles of this Issue 3/2024

Indian Journal of Pediatrics 3/2024 Go to the issue